Oncolytics Biotech (ONCY) Deferred Taxes (2009 - 2010)
Oncolytics Biotech's (ONCY) quarterly Deferred Taxes came in at -$1.1 million in Q3 2010, down 198.03% year-on-year from $1.1 million in Q3 2009, and little changed on a QoQ basis from -$1.1 million in Q2 2010.
Oncolytics Biotech (ONCY) Deferred Taxes (2009 - 2010) Analysis & Trends
Oncolytics Biotech (ONCY) has 2 years of Deferred Taxes data on file, last reported at -$1.1 million in Q3 2010.
- On a quarterly basis, Deferred Taxes fell 198.03% year-over-year to -$1.1 million in Q3 2010; TTM through Sep 2010 was -$1.7 million, a 23.05% increase from a year earlier, with the FY2009 full-year figure at -$680928.0, changed N/A from the prior year.
- Deferred Taxes for Q3 2010 stood at -$1.1 million, roughly flat from -$1.1 million in the prior quarter.
- Over the last five years, Deferred Taxes for ONCY reached as high as $1.1 million in Q3 2009 and fell as low as -$1.1 million in Q1 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Oncolytics Biotech | 372.40 Mn | 372.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2010 | -1.09 Mn |
| Jun 30, 2010 | -1.09 Mn |
| Mar 31, 2010 | 1.12 Mn |
| Dec 31, 2009 | -644,925.35 |
| Sep 30, 2009 | 1.12 Mn |
| Jun 30, 2009 | -1.12 Mn |
| Mar 31, 2009 | -1.12 Mn |